Palavras-chave
Canabidiol
Fenobarbital
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Avaliar os efeitos da administração transdérmica de canabidiol (CBD), isolado ou associado ao fenobarbital, sobre alterações comportamentais, histopatológicas e oxidativas em modelo experimental de epilepsia induzida por pilocarpina. Métodos: Foram utilizados 72 ratos Wistar distribuídos em oito grupos experimentais, submetidos à indução de epilepsia por pilocarpina e tratados por via transdérmica durante 30 dias com formulações contendo CBD e/ou fenobarbital. Realizaram-se testes comportamentais em labirinto em cruz elevado e campo aberto, análises histopatológicas e histomorfométricas do hipocampo, além da avaliação de marcadores de estresse oxidativo. As formulações nanoestruturadas também foram caracterizadas quanto à estabilidade físico-química. Resultados: Os grupos tratados com CBD apresentaram redução da hiperexcitabilidade neuronal, melhora comportamental e diminuição da atividade locomotora. Observou-se menor mortalidade neuronal, redução da gliose e preservação parcial da arquitetura hipocampal, especialmente no grupo CBD35. Esse grupo também demonstrou melhor resposta antioxidante, com aumento da atividade da superóxido dismutase e manutenção parcial da catalase. Conclusão: A administração transdérmica de CBD, principalmente associada ao fenobarbital, apresentou potencial neuroprotetor e antioxidante no modelo experimental de epilepsia, mostrando-se uma estratégia terapêutica promissora.
Referências
AEBI H. Oxygen radicals in biological systems. Methods Enzymology, 1984; 105: 121-126.
AGRAWAL S, et al. Hippocampal neuronal loss and cognitive decline in LATE-NC and ADNC among community-dwelling older persons. Alzheimer’s & Dementia, 2025; 21(2): e14500.
ARSHAD MN, NAEGELE JR. Aberrant adult neurogenesis in intractable epilepsy: can GABAergic progenitor transplantation normalize this process? Neural Regeneration Research, 2024; 19(7): 1419-1420.
ASSADPOUR E, et al. Cannabidiol-Loaded Nanocarriers and Their Therapeutic Applications. Pharmaceuticals (Basel). 2023 Mar 24;16(4):487. doi: 10.3390/ph16040487.
BENZIE IF, STRAIN JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Analytical Biochemistry, 1996; 239(1): 70-76.
BLESSING EM, et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 2015; 12(4): 825-836.
CAMPOS AC, et al. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacological Research, 2016; 112: 119-127.
CASTILLO-ARELLANO J, et al. The polypharmacological effects of cannabidiol. Molecules, 2023; 28: 3271.
DIAS FCR, et al. Hydroalcoholic extract of Pfaffia glomerata alters the organization of the seminiferous tubules by modulating the oxidative state and the microstructural reorganization of the mice testes. Journal of Ethnopharmacology, 2019; 233: 179-189.
DO VAL-DA SILVA RA, et al. Protective effects of cannabidiol against seizures and neuronal death in a rat model of mesial temporal lobe epilepsy. Frontiers in Pharmacology, 2017; 8: 131.
GHOSH S, et al. Pharmacological and therapeutic approaches in the treatment of epilepsy. Biomedicines, 2021; 9(5): 470.
GUTTERRIDGE JMC, HALLIWELL B. The measurement and mechanism of lipid peroxidation in biological systems. Trends in Biochemical Sciences, 1990; 15: 129-135.
HABIG WH, et al. Glutathione S-transferases: the first enzymatic step in mercapturic acid formation. Journal of Biological Chemistry, 1974; 249(22): 7130-7139.
HAMPSON AJ, et al. Cannabidiol and (-)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences, 1998; 95(14): 8268-8273.
HILL MN, et al. Cannabidiol and its potential therapeutic effects: a review of the neurobiological mechanisms. Journal of Neuroscience Research, 2021; 41(2): 148-161.
IBEAS BIH C, et al. Molecular targets of cannabidiol in neurological disorders. Journal of Neuroinflammation, 2015; 12: 71.
KREZYMON A, et al. Modifications of hippocampal circuits and early disruption of adult neurogenesis in the Tg2576 mouse model of Alzheimer’s disease. PLoS One, 2013; 8(9): e76497.
KREZYMON A, et al. Modifications of hippocampal circuits and early disruption of adult neurogenesis in the Tg2576 mouse model of Alzheimer’s disease. PLoS One, 2013; 8(9): e76497.
LODZKI M, et al. Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. Journal of Controlled Release, 2003; 93(3): 377-387.
LOWRY OH, et al. Protein measurement with the folin phenol reagent. Analytical Biochemistry, 1951; 193: 265-275.
MAHMOUDINOODEZH H, et al. The transdermal delivery of therapeutic cannabinoids. Pharmaceutics, 2022; 14(2): 438.
MILLAR SA, et al. A systematic review on the pharmacokinetics of cannabidiol in humans. Frontiers in Pharmacology, 2018; 9: 1365.
PARENT JM, LOWENSTEIN DH. Seizure-induced neurogenesis: are more new neurons good for an adult brain? Progress in Brain Research, 2002; 135: 121-131.
RICART-JANÉ D, et al. Anticoagulants and other preanalytical factors interfere in plasma nitrate/nitrite quantification by the Griess method. Nitric Oxide - Biology and Chemistry, 2002; 6: 178-185.
SEIBENHENER ML, WOOTEN MC. Use of the open field maze to measure locomotor and anxiety-like behavior in mice. Journal of Visualized Experiments, 2015; 96: e52434.
SIDDIQUI IA, et al. Protective effects of black tea extract on testosterone induced oxidative damage in prostate. Cancer Letters, 2005; 227: 125-132.
SIERRA A, et al. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell, 2010; 7(4): 483-495.
TASKER RC. Hippocampal selective regional vulnerability and development. Developmental Medicine & Child Neurology, 2008; 43: 6-7.
TOMSON T, et al. The pharmacological treatment of epilepsy in adults. Epileptic Disorders, 2023.
VERHEIJEN ME, et al. The pharmacology of cannabidiol in neurological disorders. Journal of Psychopharmacology, 2020; 34: 418-429.
WEN X, MA H. Cytoplasmic vacuolization: a fascinating morphological alteration from cellular stress to cell death. Cancer Science, 2025; 116(5): 1181-1192.
BERG AT, et al. FDA patient-focused drug development guidances: considerations for trial readiness in rare developmental and epileptic encephalopathies. Neurology, 2024; 102: e207958.
CAVALHEIRO EA, et al. Estudos sobre epilepsia experimental e neuroproteção. Revista Brasileira de Neurologia, 1991; 30: 12-20.
LISTER RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology, 1987; 92: 180-185.
MAKARIEVA LM, et al. Morphological and morphometric description of neurons of the sensorimotor cortex of the rat brain after ligation of the common carotid arteries. Journal of Anatomy and Histopathology, 2022; 11(1): 49-58.
MCCLEMENTS DJ. Nanoemulsions versus microemulsions: terminology, differences, and similarities. Soft Matter, 2012; 8: 1719-1729.
TISHKINA AO, et al. Chronic stress induces nonapoptotic neuronal death in the rat hippocampus. Doklady Biological Sciences, 2009; 428(1): 403-406.
VERHEIJEN ME, et al. The pharmacology of cannabidiol in the treatment of neurological disorders. Journal of Psychopharmacology, 2020; 34(4): 418-429.
ZULFIQAR NS. Pyramidal layer thinning, shrunken neurons and deep vacuolation in hippocampus due to organic lead-induced toxicity. 2014.